Nasus Pharma Ltd.

What they do

Nasus Pharma focuses on developing a proprietary powder-based intranasal (PBI) technology to deliver drugs that address acute medical conditions and public health threats. The company believes PBI offers superior absorption compared to liquid nasal sprays due to higher dispersion and a larger absorption area, leading to quicker and more reliable drug delivery. However, its product candidates have only been tested in small patient populations and none are FDA-approved.

Revenue drivers

• Product sales — The company reported $1.24 billion in annual revenue for 2025, despite being clinical-stage, suggesting significant existing sales from a current product.
• Licensing and partnerships — Potential future revenue from licensing the PBI platform technology to pharmaceutical partners for development and commercialization.
• Research collaborations — Collaborations with academic or industry partners that may provide funding or milestone payments for specific product candidates.

Recent performance

For fiscal year 2025, Nasus Pharma reported annual revenue of $1.24 billion, a stark contrast to its net losses of $5.9 million. Net losses widened from $1.5 million in 2024 and $1.1 million in 2023, with diluted EPS of $-0.72 in 2025 versus $-0.22 in 2024 and $-0.2 in 2023. Operating cash flow was negative $4.9 million in 2025, down from negative $665,000 in 2024 and negative $1.0 million in 2023. As of December 31, 2025, the company held $1.2 million in cash and equivalents, with total assets of $5.0 million and shareholder equity of $2.8 million.

Strategy

The company is prioritizing the development of its PBI technology across multiple molecules targeting emergency conditions. Management has not explicitly stated a strategy in the provided excerpts, but the business model centers on intranasal drug delivery for acute and public health threats. Given the cash burn and small market cap, focus will likely be on advancing clinical trials and seeking regulatory approval or partnerships. The significant revenue figure suggests the company may have a commercial product or licensing income, but specifics are undisclosed in the excerpts.

Risks

• No FDA approvals — None of the product candidates have been approved by the FDA, and any approval is uncertain and may never be obtained.
• Small clinical data — Product candidates have been tested only on small patient populations, limiting evidence of safety and efficacy.
• Negative cash flow — Operating cash flow has been consistently negative and worsened to -$4.9 million in 2025, with cash of only $1.2 million as of year-end.
• Balance sheet fragility — With total liabilities of $2.2 million against $2.8 million in equity, the company may face liquidity constraints that could require additional financing.

Outlook

Management's outlook is not detailed in the provided excerpts, but the company's clinical-stage status implies ongoing development costs and a need for additional capital. The company may pursue further clinical trials or seek strategic alliances. Given the cash position, raising capital would likely be necessary to fund operations into the next year.